Summary
Famotidine, a new H2-receptor antagonist was tested for drug interactions using 14C-aminopyrine and antipyrine. Elimination of these model drugs was studied before and during 8 days of famotidine dosing in 8 healthy volunteers. Famotidine 40 mg b.d. did not inhibit aminopyrine 14CO2 half-life or antipyrine clearance although an unexpected mild enzyme inducing effect could not be excluded. It is unlikely that famotidine will inhibit hepatic drug metabolism during routine clinical use as the daily dose is expected to be 40 mg/day but interactions should be looked for if more prolonged or larger doses are used.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Henry DA, MacDonald IA, Kitchingman G, Bell GD, Langman MJS (1980) Cimetidine and ranitidine: Comparisons of effects of hepatic drug metabolism. Br Med J 281: 775–777
Serlin MJ, Sibeon RG, Mossman S, Breckenridge AM, Williams JRB, Atwood JL, Willoughby JMT (1979) Cimetidine: Interaction with oral anti-coagulants in man. Lancet 2: 317–319
Salem RB, Breland BD, Mishra SK, Jordan JE (1983) Effect of cimetidine on phenytoin serum levels. Epilepsia 24: 284–288
De Angeles C, Walker SE, Bartle WR (1983) Effect of lowdose cimetidine on theophylline metabolism. Clin Pharm 2: 563–567
Pendleton RG, Torchiana ML, Chung C, Cook P, Wiese S, Clineschmidt BV (1983) Studies on MK-208 (YM-11170) a new slowly dissociable H2-receptor antagonist. Arch Int Pharmacodyn 226: 4–16
Dicentra C, Pierzchala PA, Rhymer AR, Jaffe ME (1984) Outline of clinical studies with a new H2-antagonist: famotidine. Ital J Gastroenterol 16: 181–182
Howard JM, Chremos AN, Collen MJ, McArthur KE, Cherner JA, Maton PN, Ciarleglio CA, Cornelius MJ, Gardner JD, Jensen RT (1985) Famotidine, a new, potent, long-acting, histamine H2-receptor antagonist. Comparison with cimetidine and ranitidine in the treatment of the Zollinger-Ellison syndrome. Gastroenterology 88: 1026–1033
Brodie BB, Aexlrod J, Soberman R, Levy BB (1949) The estimation of antipyrine in biological materials. J Biol Chem 179: 25–29
Henry DA, Sharpe G, Chaplain S, Cartwright S, Kitchingman G, Bell GD, Langman MJS (1979) The [14C]-aminopyrine breath test. A comparison of different forms of analysis. Br J Clin Pharmacol 8: 532–545
Staiger CL, Korodnay B, Devries JX, Weber E, Muller P, Simon B, Damman HG (1984) Comparative effects of famotidine and cimetidine on antipyrine kinetics in healthy volunteers. Br J Clin Pharmacol 18: 105
Henry DA, Kitchingman G, Langman MJS (1982) H2-receptor antagonists: The problem of hepatic drug interaction. In: Misiewicz, Wormsley (eds) The Clinical use of Ranitidine. Medicine Publishing Foundation, pp 83–88
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Somerville, K.W., Kitchingman, G.A. & Langman, M.J.S. Effect of famotidine on oxidative drug metabolism. Eur J Clin Pharmacol 30, 279–281 (1986). https://doi.org/10.1007/BF00541528
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00541528